

Introduction To Open PHACTS

Lee Harland

ConnectedDiscovery / Pfizer

Using the Power of Open PHACTS

Open PHACTS 4th Community Workshop, London, 22-23 April 2013



Introduction

- ✦ Aim of the next 2 days
- ✦ Brief background to the project
- ✦ What the “Open PHACTS Discovery Platform” actually is
- ✦ Things we worry about (so you don’t have to)

(Tomorrow)

- ✦ The “Ecosystem”, how we see it working



Using the Power of Open PHACTS, London, 22-23 April 2013



Today Is Launch Day!

[#opslaunch](#)



Using the Power of Open PHACTS, London, 22-23 April 2013

Over the next two days we will discuss:

- Open PHACTS as a unique opportunity, creating information standards, unified access points and a “data market place” across pharma companies (customers)
- What the system can offer to aid your business and what you can deliver to your users
- **Day 1:** Details on the system, the data content, the API and some use cases
- **Day 2:** User, business and strategic views. Getting your input!

At the end of the workshop, we would like to leave with:

- All participants feeling they are “up to speed” on what the Open PHACTS discovery platform is and what it offers
- Feedback on where you see the opportunities and any barriers
- Specific actions, how can we get Open PHACTS working for you?

A photograph of a rural landscape viewed through the curved, reflective surface of a car's side-view mirror. The scene shows a paved road with a yellow line curving to the right. In the distance, there is a small white silo, a cluster of dark trees, and a bare tree. The sky is clear and blue. The mirror's frame and a reflection of the car's interior are visible in the foreground.


PROJECT BACKGROUND



Using the Power of Open PHACTS, London, 22-23 April 2013

Pre-competitive Informatics:

Pharma are all accessing, processing, storing & re-processing external research data



**X Repeat @
each
company**

Lowering industry firewalls: pre-competitive informatics in drug discovery
Nature Reviews Drug Discovery (2009) 8, 701-708 doi:10.1038/nrd2944



Open PHACTS Project Partners

www.openphacts.org

Pfizer Limited – Coordinator

Universität Wien – Managing entity

Technical University of Denmark

University of Hamburg, Center for Bioinformatics

BioSolveIT GmbH

Consorci Mar Parc de Salut de Barcelona

Leiden University Medical Centre

Royal Society of Chemistry

Vrije Universiteit Amsterdam

Spanish National Cancer Research Centre

University of Manchester

Maastricht University

Aqnowledge

University of Santiago de Compostela

Rheinische Friedrich-Wilhelms-Universität Bonn

AstraZeneca

GlaxoSmithKline

Esteve

Novartis

Merck Serono

H. Lundbeck A/S

Eli Lilly

Netherlands Bioinformatics Centre


Swiss Institute of Bioinformatics

ConnectedDiscovery

EMBL-European Bioinformatics Institute


Janssen

OpenLink







Using the Power of Open PHACTS, London, 22-23 April 2013



"What is the selectivity profile of known p38 inhibitors?"



"Let me compare MW, logP and PSA for known oxidoreductase inhibitors"



"Find me compounds that inhibit targets in NFkB pathway assayed in only functional assays with a potency <1 μ M"

ChEMBL

DrugBank

Gene
Ontology

Wikipathways

GeneGo

ChEBI

UniProt

UMLS

GVKBio

ConceptWiki

ChemSpider

TrialTrove

TR Integrity



Using the Power of Open PHACTS, London, 22-23 April 2013


Business Question Driven Approach

Number	sum	Nr of 1	Question
15	12	9	All oxidoreductase inhibitors active <100nM in both human and mouse
18	14	8	Given compound X, what is its predicted secondary pharmacology? What are the on and off, target safety concerns for a compound? What is the evidence and how reliable is that evidence (journal impact factor, KOL) for findings associated with a compound?
24	13	8	Given a target find me all actives against that target. Find/predict polypharmacology of actives. Determine ADMET profile of actives.
32	13	8	For a given interaction profile, give me compounds similar to it.
37	13	8	The current Factor Xa lead series is characterised by substructure X. Retrieve all bioactivity data in serine protease assays for molecules that contain substructure X.
38	13	8	Retrieve all experimental and clinical data for a given list of compounds defined by their chemical structure (with options to match stereochemistry or not).
41	13	8	A project is considering Protein Kinase C Alpha (PRKCA) as a target. What are all the compounds known to modulate the target directly? What are the compounds that may modulate the target directly? i.e. return all cmpds active in assays where the resolution is at least at the level of the target family (i.e. PKC) both from structured assay databases and the literature.
44	13	8	Give me all active compounds on a given target with the relevant assay data
46	13	8	Give me the compound(s) which hit most specifically the multiple targets in a given pathway (disease)
59	14	8	Identify all known protein-protein interaction inhibitors

... paper coming very soon in DDT



A Precompetitive Knowledge Framework





Open PHACTS

Open Pharmacological Space




THE OPEN PHACTS DISCOVERY PLATFORM



Using the Power of Open PHACTS, London, 22-23 April 2013

Open PHACTS Elements



API

```

w_uri .
equiv_target .
et_name ;
void:inDataset <http://www.conceptwiki.
?equiv_target dc:title ?target_name;
ops:target_organism ?target_organism ;
ops:targetOfAssay ?equiv_assay ;
void:inDataset <http://data.kasabi.com/
ops:targetOfAssay owl:inverseOf chembl:hasTarget
?equiv_assay chembl:organism ?assay_organism ;
chembl:hasDescription ?assay_description
ops:assayOfActivity ?activity_uri .
ops:assayOfActivity owl:inverseOf chembl:onAssa
?activity_uri chembl:type ?std_type ;
  
```

Apps

Standards





Using the Power of Open PHACTS, London, 22-23 April 2013

www.openphacts.org/publications

HOME SITEMAP MEMBER LOGIN

About Open PHACTS Partners News & Events Documents **Open PHACTS Explorer**



Menu Documents Publications Follow us

2013

02.04.2013
Louizou A., Groth P.: On the Formulation of Performant SPARQL Queries. Journal of Web Semantics, 2 April 2013 [read](#)

2012

07.12.2012
Furlong, Laura I.: Human diseases through the lens of network biology. 7 December 2012 [read](#)

10.10.2012
Breninkmeijer C., Evelo C., Goble C., Gray A., Waagmeester A., Willighagen E.: Dataset Descriptions for the Open Pharmacological Space. 19 Oct 2012 [read](#)

04.10.2012
Goble, Groth, Mons, et al.: Theoretical and technological building blocks for an innovation accelerator. 4 October 2012 [read](#)

25.09.2012
Harland, Lee: Open PHACTS: A semantic knowledge infrastructure for public and commercial drug discovery research. Springer, Lecture Notes in Computer Science, Volume 7603, p. 1-7, 2012 [read](#)

30.08.2012
Brothwood, Jessica: Druggable and biopharmable genome annotation pipeline development. MSc Thesis, Cranfield University, GlaxoSmithKine, September 2012 [read](#)

Internal Meetings:
April 24-25, 2013
Researchathon in London at RSC
May 21-22, 2013
5th Workpackage Leader Group Meeting in Gothenburg, Sweden
Conferences:
April 22-23, 2013
4th Open PHACTS Community Workshop in London at RSC [more](#)
May 05-08, 2013
ASMC 2013

Follow us
CONTACT US
FOLLOW ON YOUTUBE
SUBSCRIBE RSS
NEWSLETTER
SHARE ON LINKEDIN
FOLLOW ON TWITTER
FOLLOW ON SLIDESHARE

Events

Key papers to cite the project

To cite the project:
Williams A., Harland L., Groth P., et al.: Open PHACTS: Semantic interoperability for drug discovery. Drug Discovery Today, June 06, 2012

To cite the Open PHACTS Discovery Platform:
Gray A., Groth P., Loizou A., et al.: Applying Linked Data Approaches to Pharmacology: Architectural Decisions and Implementation. Semantic Web Journal, April 18, 2012




Why a Semantic Technology approach?

- ❖ Different formats, different structures, different vocabularies, different concepts, different meaning
- ❖ Data should be structured (not ASCII)
- ❖ Structure should be data-oriented (not HTML)
- ❖ Meaning of data should be clear (not XML)
- ❖ Reusable mappings between data are needed (not XSLT)
- ❖ Avoid extensive schema rewriting (not data warehouses)
- ❖ Data should have standard APIs (not Flickr)
- ❖ Synergise with many public efforts



Using the Power of Open PHACTS, London, 22-23 April 2013

You!





Open PHACTS


Open Pharmacological Space



WHAT WE THINK ABOUT



Using the Power of Open PHACTS, London, 22-23 April 2013



<http://imgs.xkcd.com/comics/standards.png>




Adoption Of Standards

- ✦ Basic Semantic web standards
 - SPARQL 1.1, RDF(S), SKOS
- ✦ Dataset descriptions
 - Vocabulary of Interlinked Datasets (VoID)
 - VoID linkset descriptions
- ✦ QUDT Quantities, Units, Dimensions and Types
- ✦ Provenance
 - W3C PROV, PAV, Nanopublications
- ✦ BioPortal, ConceptWiki, ChEMBL, identifiers.org, Uniprot, ChemSpider



The Seven Deadly Sins of Bioinformatics

Professor Carole Goble The University of Manchester, UK
The myGrid project, OMII-UK



Andy Law's Third Law

“The number of unique identifiers assigned to an individual is never less than the number of Institutions involved in the study”... and is frequently many, many more.



Open PHACTS

Open Pharmacological Space



Using the Power of Open PHACTS, London, 22-23 April 2013

HELLO
my name is

~~RS_2353~~

~~GB:29384~~

~~P12047~~


~~X31045~~

~~P12047~~

Let the IMS take the strain....




Using the Power of Open PHACTS, London, 22-23 April 2013




About | More Searches | Web APIs

Gleevec




ChemSpider ID
Molecular Form
Average mass:
Monoisotopic m
▼ Systematic n
4-[(4-Methyl-1-


Structure	 Download: MOL SDF SMILES InChI Display: 2D Structure 3D Structure
Synonyms	<ul style="list-style-type: none"> Imatinib Mesylate Imatinib Methansulfonate STI-571
Brand names	<ul style="list-style-type: none"> Gleevec Glivec

ChemSpider

Drugbank



[Imatinib; 152459-95-5; sti-571 ...](#)
 MW: 493.602740 g/mol MF: C₂₉H₃₁N₇O
 IUPAC name: 4-[(4-methylpiperazin-1-yl)methy
[Active in 205 BioAssays](#) [Tested in 1376 Bio](#)
 CID: 5291
[Similar Compounds](#) [Same Parent, Connectiv](#)
[\(MeSH Keyword\)](#)



[Imatinib mesylate; Gleevec; Glivec ...](#)
 MW: 589.708400 g/mol MF: C₃₀H₃₅N₇O₄S
 IUPAC name: methanesulfonic acid; 4-[(4-meth
[Active in 35 BioAssays](#) [Tested in 679 BioAss](#)
 CID: 123596
[Similar Compounds](#) [Same Parent, Connectiv](#)
[\(MeSH Keyword\)](#)

PubChem



Its easy to integrate, difficult to integrate well:

Type a compound name:

glee

- Gleevec
- Gleevec



Dynamic Equality

Strict

Relaxed



Analysing

Browsing



Open PHACTS
Open Pharmacological Space

























Open PHACTS

Open Pharmacological Space



Search:

Molecular Topology Framework Ungroup

 Neomycin	 Neomycin undec...	 Neomycin	 Triamcinolone h...	 Neomycin	 Framycetin
 Nystatin	 Pamirine	 Polymyxin B1	 Dexamethasone	 Streptomycin	 Sulfanilamide
 Hydrocortisone	 Methylrosanilini...	 Tetracycline	 Cinchocaine	 Methylprednisol...	 Sulfacetamide
					

Filter

Provenance: On Off 🔄

Provenance Datasources

- ConceptWiki
download SD-file

- ChemSpider
Target Name







- Drugbank
Ephrin type-A receptor 7

- ChEMBL

Prepare full result set download

Download CSV-file

Prepare

Structure	Compound name	Target Organism		
<div style="text-align: center;">45</div> <div style="text-align: center;">  </div>	Sorafenib	Homo sapiens		
<div style="text-align: center;">46</div> <div style="text-align: center;">  </div>	Sorafenib	Homo sapiens	MLDQJTXFUGDVEO	Stem cell growth factor receptor
<div style="text-align: center;">47</div> <div style="text-align: center;">  </div>	Sorafenib	Homo sapiens	MLDQJTXFUGDVEO	Ephrin type-A receptor II
<div style="text-align: center;">48</div> <div style="text-align: center;">  </div>	Sorafenib	Homo sapiens	MLDQJTXFUGDVEO	Tyrosine-protein kinase ABL
<div style="text-align: center;">49</div>	Sorafenib	Homo sapiens	MLDQJTXFUGDVEO	myosin light chain kinase 2

```
<inDataset href="http://rdf.chemspider.com/void.rdf#chemSpiderDataset" />
```



To Conclude:

- ❖ Welcome!
- ❖ Open PHACTS is much more than software, it's a whole new approach (but the software is pretty cool too!)
- ❖ There's a lot of detail in the technology we won't present, but we're happy to talk about (esp. on day 2)
- ❖ We want to enhance your business – it's in both our interests

Keeping up to date

- Email us at pmu@openphacts.org to be added to the ops-dev-public mailing list
- Follow @Open_PHACTS on twitter for service info etc